Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Novartis Pharma GmbH
Femme et Homme Max 99 ans
Novartis Pharma GmbH
MAJ Il y a 5 ans
Study to assess the efficacy and safety of QVA149 in patients with COPD
To demonstrate non-inferiority of QVA149 110/50 µg to tiotropium 18 µg q.d. plus formoterol 12µg b.i.d. in terms of health related quality of life as assessed by St George’s Respiratory Questionnaire ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma GmbH
MAJ Il y a 5 ans
A one-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral ICL670 in patients diagnosed with Low and INT-1 risk Myelodysplastic Syndrome (MDS) and transfusion-dependent iron overload
The primary objective of this study is to evaluate if fixed starting doses of ICL670, dependent on transfusion history, and subsequent dose titration can provide clinically acceptable chelation among ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma GmbH
MAJ Il y a 5 ans
Study of efficacy and safety of LEE011 ribociclib (LEE011) in combination with letrozole in patients with advanced breast cancer
To assess the clinical benefit rate (CBR) after 24 weeks for ribociclib (LEE011) in combination with letrozole among postmenopausal women and men with hormone receptor positive, HER2- negative, advanc...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma GmbH
MAJ Il y a 5 ans
Comparison of safety and efficacy of vildagliptin versus NPH insulin add-on to glimepiride in patients with type 2 diabetes mellitus
1. To demonstrate that add-on to glimeperide vildagliptin is superior to NPH insulin with respect to the incidence of the combined endpoint, defined as a blood glucose target (HbA1c below 7.0%) withou...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma GmbH
MAJ Il y a 5 ans
Extension study to the expanded access study of everolimus in patients with advanced neuroendocrine tumors
To evaluate long-term safety of everolimus in patients with advanced neuroendocrine tumors of gastrointestinal or pulmonary origin.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma GmbH
MAJ Il y a 5 ans
Comparison of the glycemic profiles of vildagliptin and sitagliptin treatment in type-2 diabetic patients
To demonstrate that vildagliptin leads to a favorable hypoglycemic profile compared to sitagliptin, after 8 weeks of treatment, each, when used in combination with insulin. The hypoglycemic profile wi...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma GmbH
MAJ Il y a 5 ans
A Phase IV single arm, multicenter, open-label study assessing deep molecular response in adult patients with newly diagnosed Philadelphia chromosome positive CML in chronic phase after two years of treatment with nilotinib 300mg BID
To evaluate the proportion of patients who are in deep molecular response MR4.5 (IS) at 24 months of study treatment, measured in a standardized EUTOS MR4.5 laboratory.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma GmbH
MAJ Il y a 5 ans
A multicenter, open label, 2 period cross-over study to evaluate the Pharmacokinetics of an 8 week continuous treatment with 1x300mg/d and 2x300mg/d TOBI® inhaled with the PARI eFlow® rapid in Cystic Fibrosis (CF) Subjects
To evaluate the serum pharmacokinetics (PK) of inhaled TOBI® (AUC0-90’) of continuous daily dosing regimens with 2x300mg/d Tobramycin Nebulised Solution (=TNS) inhaled with the PARI eFlow® rapid in Cy...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma GmbH
MAJ Il y a 5 ans
Multicenter, single-arm, two-stage phase II trial of RAD001 (everolismus) with Glivec® in Glivec®-resistant patients with progressive GIST
To assess the response to treatment with RAD001 plus Glivec® at 4 months. Response is defined as progression-free survival (PFS) at 4 months.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme Max 99 ans
Novartis Pharma GmbH
MAJ Il y a 5 ans
A multi-center, randomized, open-label, controlled, one-year trial to measure the effect of zoledronic acid and alendronate on bone metabolism in post menopausal women with osteopenia and osteoporosis
To prove superiority of zoledronic acid compared to alendronate by testing the hypothesis that the change of the level of NTx in serum within the first 12 months after start of therapy in postmenopaus...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
1
2
3
4
5
6
7
8
9
10
Suivant